| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The 'permeome' of the malaria parasite: an overview of the membrane transport proteins of Plasmodium falciparum.
|
Genome Biol
|
2005
|
1.91
|
|
2
|
Presynaptic Ca2+ channels: a functional patchwork.
|
Trends Neurosci
|
2003
|
1.57
|
|
3
|
Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa.
|
Blood
|
2005
|
1.54
|
|
4
|
Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant.
|
Clin Vaccine Immunol
|
2011
|
1.51
|
|
5
|
Broadly protective Shigella vaccine based on type III secretion apparatus proteins.
|
Infect Immun
|
2011
|
1.41
|
|
6
|
CD4 T cells are the only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G).
|
J Virol
|
2002
|
1.32
|
|
7
|
Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice.
|
Neurobiol Dis
|
2003
|
1.32
|
|
8
|
Effect of homologous and heterologous prime-boost on the immune response to recombinant plague antigens.
|
Vaccine
|
2005
|
1.27
|
|
9
|
Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine.
|
Clin Vaccine Immunol
|
2010
|
1.25
|
|
10
|
Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination.
|
J Virol
|
2009
|
1.20
|
|
11
|
Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants.
|
Neurobiol Aging
|
2002
|
1.15
|
|
12
|
Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens.
|
Infect Immun
|
2005
|
1.14
|
|
13
|
Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin.
|
Vaccine
|
2009
|
1.11
|
|
14
|
Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.
|
Curr Opin Immunol
|
2011
|
1.10
|
|
15
|
Oral immunogenicity of human papillomavirus-like particles expressed in potato.
|
J Virol
|
2003
|
1.09
|
|
16
|
Presynaptic and postsynaptic mechanisms underlie paired pulse depression at single GABAergic boutons in rat collicular cultures.
|
J Physiol
|
2002
|
1.08
|
|
17
|
Binding site stoichiometry and the effects of phosphorylation on human alpha1 homomeric glycine receptors.
|
J Physiol
|
2002
|
1.06
|
|
18
|
Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans.
|
Infect Immun
|
2010
|
1.05
|
|
19
|
Association of gamma interferon and interleukin-17 production in intestinal CD4+ T cells with protection against rotavirus shedding in mice intranasally immunized with VP6 and the adjuvant LT(R192G).
|
J Virol
|
2007
|
1.04
|
|
20
|
Intranasal administration of an Escherichia coli-expressed codon-optimized rotavirus VP6 protein induces protection in mice.
|
Protein Expr Purif
|
2004
|
1.03
|
|
21
|
Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine.
|
Infect Immun
|
2013
|
1.02
|
|
22
|
Bioencapsulation of the hepatitis B surface antigen and its use as an effective oral immunogen.
|
Vaccine
|
2012
|
0.98
|
|
23
|
Antigen-specific memory T cell responses after vaccination with an oral killed cholera vaccine in Bangladeshi children and comparison to responses in patients with naturally acquired cholera.
|
Clin Vaccine Immunol
|
2012
|
0.98
|
|
24
|
Development of a Bacillus subtilis-based rotavirus vaccine.
|
Clin Vaccine Immunol
|
2010
|
0.98
|
|
25
|
Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses.
|
Vaccine
|
2002
|
0.98
|
|
26
|
Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens.
|
Vaccine
|
2007
|
0.97
|
|
27
|
IFN-gamma is the only anti-rotavirus cytokine found after in vitro stimulation of memory CD4+ T cells from mice immunized with a chimeric VP6 protein.
|
Viral Immunol
|
2007
|
0.97
|
|
28
|
Comparison of taurine- and glycine-induced conformational changes in the M2-M3 domain of the glycine receptor.
|
J Biol Chem
|
2004
|
0.97
|
|
29
|
Mice develop effective but delayed protective immune responses when immunized as neonates either intranasally with nonliving VP6/LT(R192G) or orally with live rhesus rotavirus vaccine candidates.
|
J Virol
|
2006
|
0.97
|
|
30
|
Role of B7 costimulatory molecules in the adjuvant activity of the heat-labile enterotoxin of Escherichia coli.
|
J Immunol
|
2002
|
0.96
|
|
31
|
Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model.
|
J Virol
|
2010
|
0.95
|
|
32
|
Effectiveness of the quillaja saponin semi-synthetic analog GPI-0100 in potentiating mucosal and systemic responses to recombinant HagB from Porphyromonas gingivalis.
|
Vaccine
|
2003
|
0.95
|
|
33
|
The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens.
|
Infect Immun
|
2012
|
0.93
|
|
34
|
The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant.
|
Vaccine
|
2002
|
0.92
|
|
35
|
Abeta1-15 is less immunogenic than Abeta1-40/42 for intranasal immunization of wild-type mice but may be effective for "boosting".
|
Vaccine
|
2003
|
0.91
|
|
36
|
Kinetic analysis and evaluation of the mechanisms involved in the resolution of experimental nontypeable Haemophilus influenzae-induced otitis media after transcutaneous immunization.
|
Vaccine
|
2012
|
0.90
|
|
37
|
Functional mapping of protective epitopes within the rotavirus VP6 protein in mice belonging to different haplotypes.
|
Vaccine
|
2003
|
0.90
|
|
38
|
Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD.
|
Vaccine
|
2013
|
0.89
|
|
39
|
Protection against rotavirus shedding after intranasal immunization of mice with a chimeric VP6 protein does not require intestinal IgA.
|
Virology
|
2006
|
0.89
|
|
40
|
The adjuvant double mutant Escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigens.
|
PLoS One
|
2012
|
0.88
|
|
41
|
Single epitope mucosal vaccine delivered via immuno-stimulating complexes induces low level of immunity against simian-HIV.
|
Vaccine
|
2006
|
0.87
|
|
42
|
Intrarectal immunization of mice with VP6 and either LT(R192G) or CTA1-DD as adjuvant protects against fecal rotavirus shedding after EDIM challenge.
|
Vaccine
|
2007
|
0.87
|
|
43
|
Evaluation of combinatorial vaccines against anthrax and plague in a murine model.
|
Vaccine
|
2007
|
0.86
|
|
44
|
Adenosine triphosphate acts as both a competitive antagonist and a positive allosteric modulator at recombinant N-methyl-D-aspartate receptors.
|
Mol Pharmacol
|
2004
|
0.86
|
|
45
|
Hydration effects on skin microstructure as probed by high-resolution cryo-scanning electron microscopy and mechanistic implications to enhanced transcutaneous delivery of biomacromolecules.
|
J Pharm Sci
|
2010
|
0.85
|
|
46
|
Characterization of heat-stable (STa) toxoids of enterotoxigenic Escherichia coli fused to double mutant heat-labile toxin peptide in inducing neutralizing Anti-STa antibodies.
|
Infect Immun
|
2014
|
0.84
|
|
47
|
Identification of an immunodominant CD4+ T cell epitope in the VP6 protein of rotavirus following intranasal immunization of BALB/c mice.
|
Virology
|
2007
|
0.84
|
|
48
|
Effectiveness of the B subunit of cholera toxin in potentiating immune responses to the recombinant hemagglutinin/adhesin domain of the gingipain Kgp from Porphyromonas gingivalis.
|
Vaccine
|
2005
|
0.83
|
|
49
|
Induction of increased permeability of polarized enterocyte monolayers by enterotoxigenic Escherichia coli heat-labile enterotoxin.
|
Am J Trop Med Hyg
|
2011
|
0.83
|
|
50
|
Cholera-like enterotoxins and Regulatory T cells.
|
Toxins (Basel)
|
2010
|
0.82
|
|
51
|
Dynamics of forward and reverse transport by the glial glycine transporter, glyt1b.
|
Biophys J
|
2005
|
0.82
|
|
52
|
Protection of mice against rotavirus challenge following intradermal DNA immunization by Biojector needle-free injection.
|
Vaccine
|
2007
|
0.82
|
|
53
|
Drug-disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity.
|
Br J Clin Pharmacol
|
2011
|
0.79
|
|
54
|
Automated threshold detection for auditory brainstem responses: comparison with visual estimation in a stem cell transplantation study.
|
BMC Neurosci
|
2009
|
0.78
|
|
55
|
Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system.
|
Hum Vaccin Immunother
|
2014
|
0.78
|
|
56
|
Evidence for immune-mediated reduction of viral replication in Macaca nemestrina mucosally immunized with inactivated SHIV(89.6).
|
Virology
|
2003
|
0.77
|
|
57
|
Mesenchymal stem cells as a novel vaccine platform.
|
Front Cell Infect Microbiol
|
2012
|
0.76
|
|
58
|
Induction of serum and mucosal FIV-specific immune responses by intranasal immunization with p24Gag.
|
Vaccine
|
2005
|
0.76
|
|
59
|
Unexpected modulation of recall B and T cell responses after immunization with rotavirus-like particles in the presence of LT-R192G.
|
Toxins (Basel)
|
2010
|
0.76
|